Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1629361 | 0.99 | FGFR1 (0.46) | FGFR1FLT1ACHELTA4HDRD3 | |
| SCHEMBL16424173 | 0.72 | ACHE (0.60) | FGFR1FLT1ACHELTA4HDRD3 | |
| SCHEMBL1623062 | 0.71 | FGFR1 (0.61) | FGFR1FLT1ACHELTA4HDRD3 | |
| Hydrochloric Acid SCHEMBL1622880 | 0.70 | FGFR1 (0.60) | FGFR1FLT1ACHELTA4HDRD3 | |
| SCHEMBL5639861 | 0.69 | ACHE (0.89) | ACHELTA4HDRD3HRH3CHEK2 | |
| SCHEMBL3262283 | 0.69 | FGFR1 (0.49) | FGFR1FLT1ACHELTA4HDRD3 | |
| Hydrochloric Acid SCHEMBL1629359 | 0.69 | FGFR1 (0.48) | FGFR1FLT1ACHELTA4HDRD3 | |
| SCHEMBL10247571 | 0.68 | HRH3 (0.55) | LTA4HHRH3 | |
| SCHEMBL21018072 | 0.68 | CHEK2 (0.74) | FGFR1FLT1ACHEDRD3HRH3 | |
| SCHEMBL9260985 | 0.68 | ACHE (0.89) | ACHELTA4HDRD3CHEK2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | claimed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | claimed |
| JP-2007505038-A | — | — | 2007-03-08 | — | — | JP | claimed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | FGFR1 883/4885FLT1 1395/4885ACHE 4380/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | FGFR1 846/4885FLT1 1207/4885ACHE 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.